India pharma deals hold steady at $13.9B
Indian pharma and healthcare deal value held at about $13.9 billion in Q1 FY27 and Q2 2026 despite a decline in deal volumes, led by Sun Pharmaceutical Industries’ $11.8 billion acquisition of Organon & Co. and a clear shift toward specialty portfolios, global market access, and differentiated capabilities, with investor interest centering on AI-enabled care, genomics, oncology, and advanced diagnostics, and outbound M&A accounting for the vast majority of activity.
Health · 5 sources · Jul 23, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Organon & Co.
Organon & Co. is an American pharmaceutical company originally founded in Oss, The Netherlands and now headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
Everything about Organon & Co. →- Country
- United States, Netherlands
- Headquarters
- Oss
- Inception
- 1923
- Website
- https://www.organon.com/